专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09884044B2 Treatment using dantrolene 有权
公开(公告)号：US09884044B2
公开(公告)日：2018-02-06
申请号：US15406237
申请日：2017-01-13
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/16 , A61K9/00 , A61K9/19 , A61K9/10
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

2. 发明授权

US09789090B2 Treatment using dantrolene 有权
公开(公告)号：US09789090B2
公开(公告)日：2017-10-17
申请号：US15144124
申请日：2016-05-02
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415 , A61K31/4178 , A61K9/127 , A61K47/10 , A61K47/18 , A61K9/10 , A61K9/16 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

3. 发明申请

US20170143677A1 TREATMENT USING DANTROLENE 审中-公开
公开(公告)号：US20170143677A1
公开(公告)日：2017-05-25
申请号：US15406237
申请日：2017-01-13
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/10 , A61K9/19 , A61K9/16 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

4. 发明授权

US09567302B2 Carbamate compounds and of making and using same 有权
标题翻译：氨基甲酸酯化合物及其制备和使用
公开(公告)号：US09567302B2
公开(公告)日：2017-02-14
申请号：US14383076
申请日：2013-03-15
申请人： Abide Therapeutics, Inc. , The Scripps Research Institute
发明人： Justin S. Cisar , Cheryl A. Grice , Todd K. Jones , Dong-Hui Wang , Olivia Weber , Benjamin F. Cravatt , Micah J. Niphakis , Armand Cognetta , Jae Won Chang
IPC分类号： C07D207/46 , C07D401/12 , C07D405/14 , C07D413/12 , C07D413/14 , A61K31/496 , A61K31/454 , C07D403/12 , C07D401/14 , C07D491/08 , C07D233/80 , C07D403/14 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08 , C07D209/48
CPC分类号： C07D207/46 , C07D209/48 , C07D233/80 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/08 , C07D491/107 , C07D498/08
摘要： Provided herein are carbamate compounds which may be useful in the treatment of for example, pain, solid tumors and/or obesity.
摘要翻译：本文提供了可用于治疗例如疼痛，实体瘤和/或肥胖症的氨基甲酸酯化合物。

5. 发明授权

US08685460B2 Treatment using dantrolene 有权
标题翻译：使用丹曲林治疗
公开(公告)号：US08685460B2
公开(公告)日：2014-04-01
申请号：US13353478
申请日：2012-01-19
申请人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/16 , A61K31/415 , A61K9/00 , A61K9/10 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

6. 发明申请

US20130123215A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS 有权
标题翻译： 2-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA衍生物作为甲基肽受体样-1（FPRL-1）受体调节剂
公开(公告)号：US20130123215A1
公开(公告)日：2013-05-16
申请号：US13673800
申请日：2012-11-09
申请人： Allergan, Inc.
发明人： Richard L. Beard , Vidyasagar Vuligonda , Thong Vu , John E. Donello , Veena Viswanath , Michael E. Garst
IPC分类号： C07D233/86 , C07D471/04 , C07D405/06 , C07F9/6506 , C07D401/06 , C07D403/06 , C07D403/04 , C07D235/02 , C07D409/06
CPC分类号： C07D233/86 , C07D233/80 , C07D235/02 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , C07D471/04 , C07F9/6506
摘要： The present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
摘要翻译：本发明涉及新的2,5-二氧代咪唑烷-1-基-3-苯基脲衍生物，其制备方法，含有它们的药物组合物及其作为N-甲酰基肽受体样-1（FPRL- 1）受体。

7. 发明申请

US20100137349A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS 失效
标题翻译：抗坏血酸奥沙利坦，羟丁酸和咪唑啉酮组合物
公开(公告)号：US20100137349A1
公开(公告)日：2010-06-03
申请号：US12612572
申请日：2009-11-04
申请人： Rakesh K. Jain , Eddy Low , Charles Francavilla , Timothy P. Shiau , Bum Kim , Satheesh K. Nair
发明人： Rakesh K. Jain , Eddy Low , Charles Francavilla , Timothy P. Shiau , Bum Kim , Satheesh K. Nair
IPC分类号： A61K31/438 , C07D233/40 , C07D471/10 , C07D263/20 , A61K31/421 , A61K31/4166 , A61P31/02
CPC分类号： A01N43/76 , A01N35/02 , A01N43/90 , A01N59/00 , A61K31/415 , A61K31/42 , C07D233/80 , C07D233/82 , C07D263/20 , C07D263/26 , C07D471/10 , C07D498/10
摘要： The present application relates to N-chlorinated oxazolidinone, hydantoin and imidazolidinone compounds of Formula I or pharmaceutically acceptable salts thereof, and associated compositions and methods of use as antimicrobial agents.
摘要翻译：本申请涉及式I的N-氯化恶唑烷酮，乙内酰脲和咪唑烷酮化合物或其药学上可接受的盐，以及用作抗微生物剂的相关组合物和方法。

8. 发明申请

US20100087442A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT 失效
标题翻译：化合物衍生化合物和含有化合物作为活性成分的药物
公开(公告)号：US20100087442A1
公开(公告)日：2010-04-08
申请号：US12566416
申请日：2009-09-24
申请人： Akira Hatayama , Hiroshi Tsuruta , Yasuo Ochi , Haruo Imawaka , Kazuyuki Ohmoto
发明人： Akira Hatayama , Hiroshi Tsuruta , Yasuo Ochi , Haruo Imawaka , Kazuyuki Ohmoto
IPC分类号： A61K31/501 , C07D417/12 , C07D277/18 , C07D413/12 , C07D233/32 , C07D275/02 , C07D405/06 , A61K31/427 , A61K31/421 , A61K31/4164 , A61K31/425 , A61P35/00 , A61P19/00
CPC分类号： C07D209/48 , A61K31/16 , A61K31/165 , A61K31/341 , A61K31/351 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/4152 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , C07C243/34 , C07C251/76 , C07C251/84 , C07C251/86 , C07C2601/08 , C07C2601/14 , C07D207/22 , C07D207/50 , C07D209/46 , C07D211/28 , C07D211/72 , C07D211/86 , C07D211/98 , C07D213/70 , C07D213/76 , C07D213/77 , C07D213/78 , C07D233/38 , C07D233/52 , C07D233/80 , C07D239/10 , C07D239/18 , C07D239/36 , C07D241/08 , C07D241/18 , C07D263/26 , C07D263/28 , C07D265/08 , C07D265/10 , C07D265/33 , C07D275/02 , C07D275/03 , C07D275/06 , C07D277/18 , C07D277/36 , C07D277/50 , C07D277/54 , C07D277/60 , C07D277/82 , C07D279/02 , C07D279/06 , C07D279/12 , C07D285/10 , C07D285/16 , C07D309/04 , C07D309/28 , C07D335/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D513/10 , C07F9/59 , C07F9/65583 , Y02A50/411
摘要： The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).
摘要翻译：本发明涉及式（I）的二酮肼衍生物及其药学上可接受的盐（式中的符号具有与说明书中所述相同的含义）。式（I）化合物对半胱氨酸蛋白酶具有抑制活性，可用于治疗炎性疾病，免疫疾病，缺血性疾病，呼吸系统疾病，循环系统疾病，血液病，神经元疾病，肝或胆道疾病，骨质或关节疾病，代谢疾病等。该化合物对弹性蛋白酶具有抑制活性，也可用于治疗慢性阻塞性肺疾病（慢性障碍性肺疾病）。

9. 发明申请

US20040142975A1 Beta disubstituted metalloprotease inhibitors 审中-公开
标题翻译： β二取代金属蛋白酶抑制剂
公开(公告)号：US20040142975A1
公开(公告)日：2004-07-22
申请号：US10744346
申请日：2003-12-23
申请人： The Procter &Gamble Company
发明人： Stanislaw Pikul , Norman Eugene Ohler , Kelly Michelle Solinsky , Neil Gregory Almstead , Biswanath De , Michael George Natchus
IPC分类号： A61K031/454 , A61K031/4025 , A61K031/4015 , A61K031/381
CPC分类号： C07D239/22 , C07C311/19 , C07C311/29 , C07C323/59 , C07D233/80 , C07D233/86 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D471/04 , C07D513/04
摘要： Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): 1 where R1, R2, R3, R4, R5, R6, G and Z have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of Formula I, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating metalloprotease-related maladies using the compounds or the pharmaceutical compositions.
摘要翻译：公开了作为金属蛋白酶抑制剂的化合物，其有效治疗以这些酶的过量活性为特征的病症。特别地，化合物具有根据下式（I）的结构：其中R 1，R 2，R 3，R 4，R 5，R 6，G和 Z具有说明书中描述的含义。本发明还包括式I的光学异构体，非对映异构体和对映异构体及其可药用盐，生物可水解酰胺，酯和酰亚胺。还描述了包含这些化合物的药物组合物，以及使用该化合物或药物组合物治疗金属蛋白酶相关疾病的方法。

10. 发明授权

US06696456B1 Beta disubstituted metalloprotease inhibitors 失效
标题翻译： β二取代金属蛋白酶抑制剂
公开(公告)号：US06696456B1
公开(公告)日：2004-02-24
申请号：US09687681
申请日：2000-10-13
申请人： Stanislaw Pikul , Norman Eugene Ohler , Kelly Michelle Solinsky , Neil Gregory Almstead , Biswanath De , Michael George Natchus
发明人： Stanislaw Pikul , Norman Eugene Ohler , Kelly Michelle Solinsky , Neil Gregory Almstead , Biswanath De , Michael George Natchus
IPC分类号： C07D21370
CPC分类号： C07D239/22 , C07C311/19 , C07C311/29 , C07C323/59 , C07D233/80 , C07D233/86 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D471/04 , C07D513/04
摘要： Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): where R1, R2, R3, R4, R5, R6, G and Z have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of Formula I, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating metalloprotease-related maladies using the compounds or the pharmaceutical compositions.
摘要翻译：公开了作为金属蛋白酶抑制剂的化合物，其有效治疗以这些酶的过量活性为特征的病症。特别地，化合物具有根据下式（I）的结构：其中R 1，R 2，R 3，R 4，R 5，R 6，G和 Z具有说明书中描述的含义。本发明还包括式I的光学异构体，非对映异构体和对映异构体及其可药用盐，生物可水解酰胺，酯和酰亚胺。还描述了包含这些化合物的药物组合物，以及使用该化合物或药物组合物治疗金属蛋白酶相关疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式